Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoFactor + 5-fluorouracil versus leucovorin + 5-fluorouracil in metastatic colorectal carcinoma
2004-005215-29Phase 2Completed
- Sponsor
- Mast Therapeutics, Inc.
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of folitixorin in colorectal cancer (CRC) (2 arms), sponsored by Mast Therapeutics, Inc. Primary endpoint: Incidence of grade 3 or greater toxicities. Started Feb 2005; status: completed.
02
Drugs
folitixorin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2004-005215-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005215-29.